Marker Therapeutics reported a net loss of $1.84 million for the third quarter of 2026. The company's loss per share was $0.10.

This improved from a $2.0 million net loss in the third quarter of 2025. The prior year's loss per share was $0.12.

The $0.10 loss per share beat analyst consensus estimates.

The company generated approximately $1.29 million in revenue for the quarter. This revenue primarily derived from grant income. It fell short of analysts' expectations.

Operating expenses decreased compared to the third quarter of 2025. Lower research and development costs drove this decrease.

Marker Therapeutics ended the quarter with approximately $9.0 million in cash and cash equivalents.